Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -33.82% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.82% | -- | |||
| Cost of Revenue | -48.00% | -- | |||
| Gross Profit | 36.59% | -- | |||
| SG&A Expenses | 92.95% | -- | |||
| Depreciation & Amortization | 1.77% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 52.86% | -- | |||
| Operating Income | -93.43% | -- | |||
| Income Before Tax | 40.21% | -- | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.21% | -- | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.21% | -- | |||
| EBIT | -93.43% | -- | |||
| EBITDA | -97.61% | -- | |||
| EPS Basic | 41.94% | -416.67% | |||
| Normalized Basic EPS | 77.27% | -- | |||
| EPS Diluted | 41.94% | -416.67% | |||
| Normalized Diluted EPS | 77.27% | -- | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||